News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aerpio Announces Publication Of Preclinical Data On AKB-9778 For Common Eye Diseases



9/3/2014 12:48:40 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CINCINNATI--(BUSINESS WIRE)--Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced the publication of preclinical data demonstrating that lead candidate, AKB-9778, reduces abnormal blood vessel growth and leakage in mouse models of ophthalmic diseases, such as diabetic macular edema (DME) and age-related macular degeneration. These data were published in collaboration with researchers at Johns Hopkins School of Medicine, Max Planck Institute, and Duke University in the September 2, 2014, issue of The Journal of Clinical Investigation. AKB-9778 is a small molecule activator of Tie2 currently in a Phase 2 clinical study for the treatment of DME.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES